Get the Daily Brief
Latest Biotech News
GLP‑1 patent surge — Novo Nordisk and Chinese groups file new agonists
Intellectual property activity in incretin therapeutics accelerated this week as Novo Nordisk disclosed new GLP‑1 receptor agonist polypeptide analogues and Chinese research groups and companies...
Sarepta touts three‑year durability for Elevidys — efficacy narrative returns
Sarepta released three‑year follow‑up data showing durable motor function benefits for patients treated with Elevidys (delandistrogene moxeparvovec) relative to external controls. The company says...
AI designs anti‑CRISPRs — new off‑switches for Cas editors in weeks
Researchers used de novo AI protein design to create novel anti‑CRISPR inhibitors (AIcrs) that block Cas13a activity, demonstrating functional inhibition in bacterial and human cells within an...
Eclipsebio buys Terrain Bio — RNA design meets sequencing analytics
Eclipsebio acquired Terrain Bio to combine Terrain’s machine learning RNA analytics with Eclipsebio’s sequencing-first validation platform, aiming to create an end‑to‑end RNA therapeutic design,...
10x Genomics pivots toward clinical diagnostics — CLIA lab, hospital collaborations
10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute and plans to build a CLIA‑certified lab to support...
Worldwide Clinical Trials buys Catalyst — CRO consolidation in oncology
Worldwide Clinical Trials agreed to acquire UK‑based Catalyst Clinical Research to bolster early‑phase oncology capabilities and add functional service provider (FSP) offerings. The deal — cited...
Boehringer pens €1.05B deal for Simcere's IBD bispecific
Boehringer Ingelheim struck a multi-part agreement with Shanghai-based Simcere to acquire rights to a preclinical TL1A×IL‑23p19 bispecific for inflammatory bowel disease (IBD). The deal includes a...
Roche’s GLP‑1/GIP posts 22.5% weight loss — heads to phase 3
Roche reported strong mid‑stage results for its most advanced obesity program and moved the asset toward global phase 3 testing. One Roche report showed about an 18.3% placebo‑corrected weight...
Corxel closes $287M to advance oral GLP‑1 CX11
Corxel Pharmaceuticals secured $287 million in Series D financing to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The...
TRexBio nets $50M to push Treg programs into clinic
Bay Area immunology startup TRexBio announced an additional $50 million to its 2024 Series B to support clinical advancement of regulatory T‑cell (Treg) programs. The proceeds will underwrite...
Eclipsebio buys Terrain Bio — expands RNA design‑to‑manufacturing stack
Eclipsebio completed the acquisition of Terrain Bio to accelerate its end‑to‑end RNA therapeutic platform by adding Terrain’s machine‑learning RNA analytics and design capabilities. Eclipsebio...
AI‑designed anti‑CRISPRs... rapid Cas13 inhibitors emerge
A team from Monash University and the University of Melbourne published a de novo protein‑design workflow that used generative AI to create artificial anti‑CRISPR proteins (AIcrs) that block...
Fortitude launches GLUE‑DAC to tackle ADC resistance — $13M seed
Fortitude Biomedicines launched with $13 million in seed funding to develop GLUE‑DACs—antibody‑drug conjugates that use targeted protein degraders (molecular glues) as payloads. The company argues...
FDA greenlights Life Biosciences gene‑therapy study to test cellular 'rewinding'
The US Food and Drug Administration granted approval for Life Biosciences to start a clinical study testing a gene‑therapy approach designed to reverse cellular aging markers. The greenlight...
Industry splits over FDA plan to cut comparative efficacy studies for biosimilars
The FDA’s draft guidance proposing to remove routine comparative efficacy studies (CES) for most biosimilars in favor of comparative analytical assessments (CAA) has sparked debate across the...
Parse Biosciences, Graph Therapeutics to build massive immune perturbation atlas
Parse Biosciences and Graph Therapeutics announced a strategic collaboration to create one of the largest immune‑cell perturbation atlases to date. The partnership will combine Graph’s...
AI‑designed anti‑CRISPRs: Rapid off‑switches for Cas13
Researchers at Monash University and the University of Melbourne reported de novo, AI‑designed protein inhibitors that block Cas13a activity, accelerating discovery of anti‑CRISPRs. Published in...
Photon‑counting CT: Lower dose, same cardiac contrast‑to‑noise
A study published in Pediatric Radiology led by Narum, Yu, and McCollough demonstrated that high‑pitch cardiac CT using photon‑counting detectors achieves equivalent contrast‑to‑noise ratio (CNR)...
10x Genomics pivots to clinic: partnerships and CLIA plan
10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute while committing to build a CLIA‑certified lab within...
Eclipsebio buys Terrain Bio: Push to an end‑to‑end RNA platform
Eclipsebio acquired Terrain Bio to combine Terrain’s machine‑learning RNA analytics with Eclipsebio’s sequencing‑first RNA characterization, aiming to build an end‑to‑end RNA design, manufacturing...